These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 35151823)

  • 1. Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.
    Shahin K; Zhang L; Mehraban MH; Collard JM; Hedayatkhah A; Mansoorianfar M; Soleimani-Delfan A; Wang R
    Microb Pathog; 2022 Mar; 164():105442. PubMed ID: 35151823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
    Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
    Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2: previous coronaviruses, immune response, and development of vaccines.
    De León-Rodríguez SG; Hernández-Rico B; Olmo-Vázquez GD; Cruz-Dávalos I; Bonifaz LC
    Bol Med Hosp Infant Mex; 2020; 77(5):252-261. PubMed ID: 33064679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
    Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
    Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.
    Kim KD; Hwang I; Ku KB; Lee S; Kim SJ; Kim C
    J Microbiol Biotechnol; 2020 Aug; 30(8):1109-1115. PubMed ID: 32627758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
    Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
    Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 Vaccine: A comprehensive status report.
    Kaur SP; Gupta V
    Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of Early SARS-CoV-2 and Cross-Coronavirus Immunity.
    Loos C; Atyeo C; Fischinger S; Burke J; Slein MD; Streeck H; Lauffenburger D; Ryan ET; Charles RC; Alter G
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32878931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phage-Displayed Mimotopes of SARS-CoV-2 Spike Protein Targeted to Authentic and Alternative Cellular Receptors.
    Petrenko VA; Gillespie JW; De Plano LM; Shokhen MA
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
    Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
    EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
    Yashavantha Rao HC; Jayabaskaran C
    J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Breadth of Bacteriophages Contributing to the Development of the Phage-Based Vaccines for COVID-19: An Ideal Platform to Design the Multiplex Vaccine.
    Ul Haq I; Krukiewicz K; Yahya G; Haq MU; Maryam S; Mosbah RA; Saber S; Alrouji M
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36675046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.
    di Mauro G; Scavone C; Rafaniello C; Rossi F; Capuano A
    Int Immunopharmacol; 2020 Jul; 84():106519. PubMed ID: 32311668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.
    Zheng C; Kar I; Chen CK; Sau C; Woodson S; Serra A; Abboud H
    CNS Drugs; 2020 Sep; 34(9):879-896. PubMed ID: 32780300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Overview of Antiviral Properties of Bacteriophages with Emphasis on the Treatment of COVID-19 Infection.
    Jalili M; Ansari N; Pourhossein B; Fazeli M; Jalilian FA
    Infect Disord Drug Targets; 2022; 22(6):e240122200472. PubMed ID: 35068397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.